Literature DB >> 15749808

Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways.

Y L Bao1, K Tsuchida, B Liu, A Kurisaki, T Matsuzaki, H Sugino.   

Abstract

Activin has previously been shown to act as a nerve cell survival factor and to have neurotrophic effects on neurons. However, the role of activin in regulating neurotransmitter expression in the central nervous system and the exact mechanisms involved in this process are poorly understood. In the present study, we report that activin A and basic fibroblast growth factor (bFGF) synergistically increased the protein level of tyrosine hydroxylase (TH), and also greatly increased the TH mRNA level, in both mouse E14 striatal primary cell cultures and the hippocampal neuronal cell line HT22. Activin A and bFGF cooperatively stimulated nuclear translocation of Smad3 and specifically activated ERK1/2, but not p38 or JNK. Interestingly, a specific inhibitor for MEK, U0126, efficiently blocked the induction of TH promoter activity by activin A and bFGF, indicating that activin A collaborated with bFGF signaling to induce the TH gene through selective activation of ERK-type MAP kinase in mouse striatal and HT22 cells. These data suggest that activin A may act in concert with bFGF for the development of TH-positive neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749808     DOI: 10.1677/joe.1.05978

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

1.  The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling.

Authors:  Siyun Liao; Darius Porter; Alana Scott; Gilbert Newman; Thomas Doetschman; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2006-12-05       Impact factor: 5.000

Review 2.  The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy.

Authors:  Michael Grusch; Michaela Petz; Thomas Metzner; Deniz Oztürk; Doris Schneller; Wolfgang Mikulits
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

3.  Delayed activin A administration attenuates tissue death after transient focal cerebral ischemia and is associated with decreased stress-responsive kinase activation.

Authors:  Shibani S Mukerji; Riley N Rainey; Jamie L Rhodes; Alison K Hall
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

4.  Activin acts with nerve growth factor to regulate calcitonin gene-related peptide mRNA in sensory neurons.

Authors:  P Xu; A K Hall
Journal:  Neuroscience       Date:  2007-09-21       Impact factor: 3.590

Review 5.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Cancers (Basel)       Date:  2014-12-30       Impact factor: 6.639

6.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

7.  Activin A inhibition attenuates sympathetic neural remodeling following myocardial infarction in rats.

Authors:  Juan Hu; Xi Wang; Yan-Hong Tang; Ying-Guang Shan; Qiang Zou; Zhi-Qiang Wang; Cong-Xin Huang
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952

8.  Activin A-Mediated Regulation of XT-I in Human Skin Fibroblasts.

Authors:  Thanh-Diep Ly; Ricarda Plümers; Bastian Fischer; Vanessa Schmidt; Doris Hendig; Joachim Kuhn; Cornelius Knabbe; Isabel Faust
Journal:  Biomolecules       Date:  2020-04-14

9.  Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling.

Authors:  Pauline C Xu; Mikyoung You; Seok-Yeong Yu; Yi Luan; Maya Eldani; Thomas C Caffrey; Paul M Grandgenett; Kelly A O'Connell; Surendra K Shukla; Chandramohan Kattamuri; Michael A Hollingsworth; Pankaj K Singh; Thomas B Thompson; Soonkyu Chung; So-Youn Kim
Journal:  Sci Rep       Date:  2022-01-31       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.